Guggenheim analyst Evan Wang upgraded Invivyd to Buy from Neutral with a $9 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD:
- Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
- Invivyd (NASDAQ:IVVD): Innovative COVID Treatment but a Speculative Investment
- Invivyd’s Financial Stability Hangs in the Balance as HHS Reviews PEMGARDA’s Emergency Use Authorization
- Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
- Invivyd sees cash runway into 4Q24